European Companies Search Engine
EU funding (€4,087,421): A new generation of microbial expression hosts and tools for the production of biotherapeutics and high-value enzymes Hor 14 Nov 2018 EU Research and Innovation programme "Horizon"
Overview
Text
A new generation of microbial expression hosts and tools for the production of biotherapeutics and high-value enzymes
The ‘SECRETERS’ partnership aims to bring about a step change in the production of recombinant proteins, particularly Biotherapeutics and Industrial Enzymes. Both are critical products for the EU biotechnology sector, with combined markets in excess of $140 billion p.a.; the former are essential for the treatment of major diseases whereas the latter permeate every aspect of our daily life. Many proteins in these categories pose severe problems in production, especially disulphide-bonded proteins and new format 'difficult-to-express' proteins. SECRETERS will train a team of 15 ESRs to develop a new generation of super-producing microbial production hosts, including Escherichia coli, Bacillus species and the yeast Pichia pastoris. The project capitalises on a series of recent innovations and involves close collaboration between 5 academic Beneficiaries, who provide world-leading expertise in redox chemistry, synthetic biology and protein expression, and 5 non-academic Beneficiaries, who include some of the world's premier biotherapeutic and industrial enzyme companies. It will enable the biotherapeutics industry to produce challenging medicines at lower costs, resulting in new drugs and wider patient access, and allow the enzymes industry to deliver a range of powerful new products. SECRETERS will equip ESRs with the interdisciplinary and intersectoral skills required to thrive in these industries, with quality assurance systems embedded throughout the programme and a commitment to a wide-ranging dissemination/outreach programme. Based on a responsible innovation approach, with clear foci on research and entrepreneurial training, SECRETERS will deliver a team of superbly-trained scientists, poised to engage in some of Europe's most important biotechnology sectors.
Funded Companies:
| Company name | Funding amount |
| Biomin Holding GmbH | ? |
| AB Enzymes GmbH | €252,788 |
| Academisch Ziekenhuis Groningen | €531,240 |
| Acib GmbH | €528,414 |
| Boehringer Ingelheim RCV GmbH & Co. KG | €264,207 |
| Celltech R&D Ltd. | €303,173 |
| Humboldt-Universitaet ZU Berlin | €252,788 |
| Lonza AG | €281,277 |
| Oulun Yliopisto | €561,612 |
| UCB Pharma SA | €0.00 |
| Universitaet Greifswald | €252,788 |
| Universitatsmedizin Greifswald KöR | €252,788 |
| University of Kent | €606,345 |
Source: https://cordis.europa.eu/project/id/813979
The filing refers to a past date, and does not necessarily reflect the current state. The latest known state is available on the following page: Biomin Holding GmbH, Getzersdorf, Austria.
